Background
Hyponatremia is the most common electrolyte imbalance in hospitalized patients, afflicting at least 30% of patients in medical, surgical and psychiatric wards [
1,
2]. Hyponatremia is a complicated condition that has been associated with all-cause mortality [
3]; length of inpatient stay [
4]; gait and attention impairments [
5]; bone fractures [
6,
7]; and perioperative complications, including 30-day morbidity and mortality [
8,
9]. Most studies that have evaluated the outcomes associated with hyponatremia restricted their analyses to hospitalized patients with pre-existing medical conditions, such as congestive heart failure, chronic kidney disease and liver cirrhosis. Although hypernatremia is also associated with increased mortality, most studies have focused on hyponatremia [
4]. Hyponatremia is common in patients presenting with acute pulmonary embolism [
10,
11], while hypernatremia is associated with increased risk of venous thromboembolism (VTE) [
12]. To date, no study has evaluated the association between hyponatremia and the occurrence of thromboembolic events.
VTE includes both deep vein thrombosis and pulmonary embolism and is a major cause of morbidity and mortality worldwide. Approximately 1 in 1000 adults is affected by VTE annually, with the incidence increasing with age [
13]. VTE ranks third among cardiovascular diseases, preceded only by coronary artery disease and cerebrovascular disease [
14]. The incidence of VTE is increased 100-fold higher in hospitalized patients than in the general population [
15], and VTE is detected in approximately 80% of surgical and medical patients who are not placed on thromboprophylaxis [
16].
Our objective was to perform a population-based retrospective cohort study of patients in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database to evaluate the association between sodium imbalances and the incidence of VTE and other selected perioperative outcomes.
Results
For the 1,108,704 patients in this study, the mean age was 57.70 years (SD = 16.69), and 56.2% of patients were female. Sodium levels were normal in 1,010,167 patients, 87,476 had hyponatremia, and 11,061 had hypernatremia. Table
1 presents demographics and baseline patient characteristics for each of the sodium groups. Compared with patients with normal sodium levels, patients with hyponatremia and hypernatremia were more likely to be older, inpatients, in a high American Society of Anesthesiologists (ASA) class, exposed to prolonged anesthesia, emergency cases, and under a “do not resuscitate” status. Additionally, these patients were more likely to have partially or totally dependent functional status, have lost more than 10% of their body weight in the prior 6 months, have abnormal pre-operative laboratory studies, and receive perioperative transfusions. Patients with hyponatremia and hypernatremia also had a higher prevalence of dyspnea, diabetes, systemic sepsis, and cardiovascular, respiratory, hepatobiliary, renal, neurological, and hematological-oncological disorders; chronic steroid use; operations within the past month; and infected surgical wounds (Table
1). Patients with normal sodium levels were more likely to be younger than 50 years of age, undergo gynecological, orthopedic, urological and plastic surgeries, have an independent functional status and have a BMI > 35. Patients with hyponatremia were more likely to be male; have undergone thoracic, vascular and cardiac surgeries; have smoked within 1 year; drink more than two drinks per day; and have a BMI < 35. Conversely, patients with hypernatremia were more likely to be non-white, have undergone general and otolaryngology surgeries, have undergone general anesthesia and have been in a coma for more than 24 h (Table
1).
Table 1
Baseline patient characteristics across three categories of blood sodium levels
Age | 61.82 ± 16.52 | 57.29 ± 16.65 | 63.38 ± 15.89 | < 0.0001 |
< 50 | 19,723 (22.6) | 316,094 (31.3) | 2015 (18.2) | < 0.0001 |
50–64 | 26,535 (30.3) | 330,181 (32.7) | 3500 (31.6) |
65–79 | 27,788 (31.8) | 271,429 (26.9) | 3653 (33.0) |
≥ 80 | 13,430 (15.4) | 92,463 (9.2) | 1893 (17.1) |
Sex, female | 44,389 (50.9) | 570,528 (56.6) | 6142 (55.6) | < 0.0001 |
Race, White | 66,224 (84.8) | 759,216 (84.6) | 7777 (78.0) | < 0.0001 |
Surgery type |
General surgery | 54,423 (62.2) | 656,018 (64.9) | 7529 (68.1) | < 0.0001 |
Gynecology | 1503 (1.7) | 35,143 (3.5) | 242 (2.2) |
Neurosurgery | 2234 (2.6) | 26,292 (2.6) | 262 (2.4) |
Orthopedics | 6831 (7.8) | 87,304 (8.6) | 782 (7.1) |
Otolaryngology (ENT) | 922 (1.1) | 15,953 (1.6) | 206 (1.9) |
Plastics | 615 (0.7) | 12,522 (1.2) | 150 (1.4) |
Thoracic | 1289 (1.5) | 10,221 (1.0) | 128 (1.2) |
Urology | 2400 (2.7) | 39,573 (3.9) | 361 (3.3) |
Vascular | 15,853 (18.1) | 116,611 (11.5) | 1317 (11.9) |
Cardiac surgery | 1404 (1.6) | 10,524 (1.0) | 83 (0.8) |
Principal anesthesia technique, general | 80,842 (92.4) | 929,863 (92.1) | 10,238 (92.6) | < 0.0001 |
ASA classification |
I-II | 25,653 (29.4) | 512,018 (50.8) | 3642 (33.0) | < 0.0001 |
III | 45,074 (51.7) | 422,264 (41.9) | 4666 (42.3) |
IV-V | 16,531 (18.9) | 73,419 (7.3) | 2721 (24.7) |
Wound classification, dirty/infected | 17,210 (19.7) | 59,804 (5.9) | 1163 (10.5) | < 0.0001 |
Inpatient status | 74,600 (85.3) | 704,245 (69.7) | 8451 (76.4) | < 0.0001 |
Emergency case | 25,053 (28.6) | 123,927 (12.3) | 2396 (21.7) | < 0.0001 |
Transfusion in 72 h before surgery | 1992 (2.3) | 8644 (0.9) | 643 (5.8) | < 0.0001 |
Do not resuscitate (DNR) status | 1601 (1.8) | 6425 (0.6) | 306 (2.8) | < 0.0001 |
Functional health status before surgery |
Independent | 73,530 (84.2) | 952,051 (94.4) | 8620 (78.1) | < 0.0001 |
Partially dependent | 10,052 (11.5) | 42,984 (4.3) | 978 (8.9) |
Totally dependent | 3708 (4.3) | 14,080 (1.4) | 1439 (13.0) |
Dyspnea | 13,284 (15.2) | 106,592 (10.6) | 1755 (15.9) | < 0.0001 |
CHF 30 days before surgery | 2530 (2.9) | 9234 (0.9) | 443 (4.0) | < 0.0001 |
History of angina 1 month before surgery | 1579 (1.8) | 10,498 (1.0) | 163 (1.5) | < 0.0001 |
History of MI 6 months before surgery | 1650 (1.9) | 7518 (0.7) | 267 (2.4) | < 0.0001 |
Previous PCI | 7353 (8.4) | 61,587 (6.1) | 881 (8.0) | < 0.0001 |
Previous cardiac surgery | 8133 (9.3) | 59,855 (5.9) | 948 (8.6) | < 0.0001 |
Hypertension requiring medication | 55,678 (63.7) | 510,100 (50.5) | 6682 (60.4) | < 0.0001 |
History of revascularization/amputation for peripheral vascular disease | 8298 (9.5) | 40,414 (4.0) | 580 (5.2) | < 0.0001 |
Smoking within 1 year | 22,555 (25.8) | 197,346 (19.5) | 2045 (18.5) | < 0.0001 |
Current pneumonia | 1537 (1.8) | 4815 (0.5) | 514 (4.7) | < 0.0001 |
History of severe COPD | 8372 (9.6) | 52,570 (5.2) | 967 (8.7) | < 0.0001 |
Ventilator dependent | 1926 (2.2) | 7756 (0.8) | 1193 (10.8) | < 0.0001 |
Ascites | 2427 (2.8) | 6325 (0.6) | 286 (2.6) | < 0.0001 |
Esophageal varices | 302 (0.4) | 1017 (0.1) | 27 (0.2) | < 0.0001 |
Acute renal failure | 1800 (2.1) | 5066 (0.5) | 336 (3.0) | < 0.0001 |
Currently on dialysis | 4758 (5.4) | 18,196 (1.8) | 353 (3.2) | < 0.0001 |
Impaired sensorium | 2018 (2.3) | 6524 (0.7) | 660 (6.0) | < 0.0001 |
Coma > 24 h | 136 (0.2) | 596 (0.1) | 99 (0.9) | < 0.0001 |
History of transient ischemic attacks (TIA) | 3662 (4.2) | 31,358 (3.1) | 421 (3.8) | < 0.0001 |
CVA/stroke with neurological deficit | 3432 (3.9) | 24,497 (2.4) | 630 (5.7) | < 0.0001 |
CVA/stroke with no neurological deficit | 2941 (3.4) | 21,936 (2.2) | 345 (3.1) | < 0.0001 |
Tumor involving CNS | 498 (0.6) | 3703 (0.4) | 62 (0.6) | < 0.0001 |
Bleeding disorders | 9989 (11.4) | 57,672 (5.7) | 1195 (10.8) | < 0.0001 |
> 10% loss body weight in previous 6 months | 4158 (4.8) | 19,804 (2.0) | 376 (3.4) | < 0.0001 |
Disseminated cancer | 3694 (4.2) | 21,246 (2.1) | 329 (3.0) | < 0.0001 |
Chemotherapy ≤30 days pre-operative | 2051 (2.3) | 14,897 (1.5) | 239 (2.2) | < 0.0001 |
Radiotherapy in last 90 days | 1011 (1.2) | 7705 (0.8) | 100 (0.9) | < 0.0001 |
BMI | 28.40 ± 8.15 | 30.31 ± 8.42 | 29.57 ± 8.30 | < 0.0001 |
< 18.5 | 4085 (4.9) | 20,342 (2.1) | 343 (3.2) | < 0.0001 |
18.5–24.9 | 27,699 (33.1) | 249,205 (25.3) | 2895 (27.3) |
25.0–29.9 | 24,643 (29.4) | 300,443 (30.5) | 3209 (30.3) |
30.0–34.9 | 13,555 (16.2) | 192,841 (19.6) | 2068 (19.5) |
≥ 35.0 | 13,716 (16.4) | 221,151 (22.5) | 2083 (19.7) |
Diabetes mellitus with oral agents or insulin | 23,275 (26.6) | 167,543 (16.6) | 2174 (19.7) | < 0.0001 |
Alcohol > 2 drinks/day 2 wks before admission | 4925 (5.6) | 25,735 (2.6) | 323 (2.9) | < 0.0001 |
Open wound/wound infection | 11,046 (12.6) | 43,031 (4.3) | 1120 (10.1) | < 0.0001 |
Steroid use for chronic condition | 4717 (5.4) | 32,860 (3.3) | 591 (5.3) | < 0.0001 |
Systemic sepsis | 21,684 (25.0) | 72,666 (7.3) | 2411 (21.9) | < 0.0001 |
Prior operation within 30 days | 6239 (7.1) | 25,921 (2.6) | 960 (8.7) | < 0.0001 |
Thromboembolism occurred in 1.0% of patients in the normal sodium group compared with 1.8% in the hyponatremia group (unadjusted OR 1.89, 95% CI 1.79–2.00) and 2.5% in the hypernatremia group (unadjusted OR 2.64, 95% CI 2.34–2.98) (Table
2). Crude mortality was 1.4% for the normal sodium group compared with 5.1% for the hyponatremia group (unadjusted OR 3.85, 95% CI 3.72–3.98) and 9.2% for the hypernatremia group (unadjusted OR 7.20, 95% CI 6.73–7.69) (Table
2). Crude composite morbidity was 7.3% for the normal sodium group compared with 16.9% for the hyponatremia group (unadjusted OR 2.59, 95% CI 2.54–2.64) and 22.1% for the hypernatremia group (unadjusted OR 3.61, 95% CI 3.45–3.78) (Table
2). Bleeding occurred in 4.3% of patients with normal sodium levels compared with 9.3% in those with hyponatremia (unadjusted OR 2.30, 95% CI 2.24–2.36) and 9.4% in those with hypernatremia (unadjusted OR 2.32, 95% CI 2.18–2.48). Of patients with normal sodium levels, 4.5% had subsequent surgery, and 5.9% were readmitted; by comparison, among patients with hyponatremia, these values were 9.7% (unadjusted OR 2.30, 95% CI 2.25–2.36) and 9.0% (unadjusted OR 1.59, 95% CI 1.52–1.67), respectively; and they were 9.1% (unadjusted OR 2.14, 95% CI 2.00–2.28) and 6.7% (unadjusted OR 1.15, 95% CI 1.00–1.33), respectively, for patients with hypernatremia (Table
2).
Table 2
Unadjusted analyses for associations between blood sodium levels and outcomes
Thromboembolism | 1577 (1.8) | 9705 (1.0) | 276 (2.5) | 1.89 (1.79–2.00) | Reference | 2.64 (2.34–2.98) |
Mortality | 4479 (5.1) | 13,972 (1.4) | 1014 (9.2) | 3.85 (3.72–3.98) | Reference | 7.20 (6.73–7.69) |
Composite morbiditya | 14,795 (16.9) | 73,563 (7.3) | 2442 (22.1) | 2.59 (2.54–2.64) | Reference | 3.61 (3.45–3.78) |
Wound | 3908 (4.5) | 23,316 (2.3) | 439 (4.0) | 1.98 (1.91–2.05) | Reference | 1.75 (1.59–1.93) |
Cardiac | 1694 (1.9) | 7472 (0.7) | 263 (2.4) | 2.65 (2.51–2.80) | Reference | 3.27 (2.89–3.70) |
Respiratory | 7772 (8.9) | 31,741 (3.1) | 1639 (14.8) | 3.01 (2.93–3.08) | Reference | 5.36 (5.08–5.66) |
Urinary | 1724 (2.0) | 7627 (0.8) | 378 (3.4) | 2.64 (2.51–2.79) | Reference | 4.65 (4.19–5.17) |
CNS | 655 (0.8) | 3938 (0.4) | 135 (1.2) | 1.93 (1.77–2.10) | Reference | 3.16 (2.66–3.75) |
Sepsis | 5618 (6.4) | 25,568 (2.5) | 870 (7.9) | 2.64 (2.57–2.72) | Reference | 3.29 (3.06–3.53) |
Bleeding | 8128 (9.3) | 43,090 (4.3) | 1036 (9.4) | 2.30 (2.24–2.36) | Reference | 2.32 (2.18–2.48) |
Return to operation room | 8490 (9.7) | 45,091 (4.5) | 1004 (9.1) | 2.30 (2.25–2.36) | Reference | 2.14 (2.00–2.28) |
Readmission (related)b | 2062 (9.0) | 16,099 (5.9) | 203 (6.7) | 1.59 (1.52–1.67) | Reference | 1.15 (1.00–1.33) |
After adjusting for potential confounders, hyponatremia was significantly and independently associated with an increased risk of thromboembolism (adjusted OR 1.43, 95% CI 1.36–1.52), mortality (adjusted OR 1.39, 95% CI 1.34–1.45), composite morbidity (adjusted OR 2.15, 95% CI 2.11–2.19), major bleeding (adjusted OR 1.96, 95% CI 1.91–2.01), return to operation room (adjusted OR 1.46, 95% CI 1.42–1.50) and readmission (adjusted OR 1.21, 95% CI 1.15–1.27) (Table
3). Hypernatremia was also significantly and independently associated with an increased risk of thromboembolism (adjusted OR 1.57, 95% CI 1.38–1.78), mortality (adjusted OR 1.39, 95% CI 1.27–1.52), composite morbidity (adjusted OR 3.33, 95% CI 3.18–3.49), major bleeding (adjusted OR 2.0, 95% CI 1.87–2.13), and return to operation room (adjusted OR 0.92, 95% CI 0.80–1.06) (Table
3).
Table 3
Adjusted analyses for associations between blood sodium levels and outcomes
Thromboembolism | 1.43 (1.36–1.52) | Reference | 1.57 (1.38–1.78) |
Mortality | 1.39 (1.34–1.45) | Reference | 1.39 (1.27–1.51) |
Composite morbiditya | 2.15 (2.11–2.19) | Reference | 3.33 (3.18–3.49) |
Wound | 1.27 (1.22–1.32) | Reference | 1.25 (1.13–1.38) |
Cardiac | 1.24 (1.17–1.31) | Reference | 1.38 (1.21–1.57) |
Respiratory | 1.77 (1.72–1.82) | Reference | 1.93 (1.80–2.07) |
Urinary | 2.28 (2.16–2.40) | Reference | 3.96 (3.56–4.40) |
CNS | 1.45 (1.33–1.57) | Reference | 2.25 (1.89–2.68) |
Sepsis | 1.72 (1.67–1.78) | Reference | 2.11 (1.96–2.28) |
Bleeding | 1.96 (1.91–2.01) | Reference | 2.00 (1.87–2.13) |
Return to operation room | 1.46 (1.42–1.50) | Reference | 1.39 (1.30–1.49) |
Readmission (related)b | 1.21 (1.15–1.27) | Reference | 0.92 (0.80–1.06) |
The effect of hyponatremia on thromboembolic outcome was evident across all age groups, both sexes, non-orthopedic patients, patients with or without steroid treatment, patients with a BMI > 18.5, patients with or without cancer and patients with or without chemotherapy (Table
4). The effect of hypernatremia on thromboembolic outcome was evident across all age groups, both sexes, non-orthopedic patients, patients not on steroids, patients with a BMI > 18.5, patients with or without cancer and patients not receiving chemotherapy (Table
4).
Table 4
Stratified analyses for associations between blood sodium levels and VTE outcome
Thromboembolism | 1.43 (1.36–1.52) | Reference | 1.57 (1.38–1.78) |
Age |
< 50 (n = 337,832) | 1.68 (1.45–1.94) | Reference | 1.65 (1.14–2.38) |
50–64 (n = 360,216) | 1.65 (1.49–1.83) | Reference | 1.42 (1.11–1.82) |
65–79 (n = 302,870) | 1.28 (1.17–1.41) | Reference | 1.67 (1.37–2.03) |
≥ 80 (n = 107,786) | 1.17 (1.02–1.33) | Reference | 1.40 (1.06–1.83) |
Sex |
Male (n = 484,893) | 1.37 (1.27–1.48) | Reference | 1.54 (1.29–1.84) |
Female (n = 623,811) | 1.48 (1.36–1.60) | Reference | 1.57 (1.31–1.88) |
Surgical specialty |
Non-orthopedic (n = 1,013,787) | 1.47 (1.39–1.56) | Reference | 1.62 (1.43–1.85) |
Orthopedic (n = 94,917) | 1.10 (0.89–1.37) | Reference | 0.71 (0.34–1.51) |
Steroid use for chronic condition |
No (n = 1,070,536) | 1.45 (1.37–1.54) | Reference | 1.66 (1.46–1.89) |
Yes (n = 38,168) | 1.26 (1.06–1.51) | Reference | 0.86 (0.53–1.39) |
BMI |
< 18.5 (n = 24,770) | 1.28 (1.00–1.63) | Reference | 1.68 (0.92–3.07) |
18.5–24.9 (n = 279,799) | 1.51 (1.36–1.66) | Reference | 1.52 (1.19–1.95) |
25.0–29.9 (n = 328,295) | 1.44 (1.30–1.60) | Reference | 1.50 (1.17–1.93) |
30.0–34.9 (n = 238,890) | 1.30 (1.15–1.48) | Reference | 1.45 (1.12–1.89) |
≥ 35.0 (n = 236,950) | 1.52 (1.32–1.74) | Reference | 1.82 (1.39–2.38) |
Presence of active cancera |
No (n = 1,068,670) | 1.42 (1.34–1.51) | Reference | 1.53 (1.34–1.74) |
Yes (n = 40,034) | 1.25 (1.04–1.49) | Reference | 1.55 (1.29–1.85) |
Chemotherapy for malignancy ≤30 days pre-surgery |
No (n = 1,091,517) | 1.42 (1.34–1.51) | Reference | 1.57 (1.38–1.78) |
Yes (n = 17,187) | 1.67 (1.29–2.16) | Reference | 1.57 (0.79–3.13) |
The median time from blood draw to surgery was 4 days. Because sodium levels vary over time, we performed a restricted sensitivity analysis for patients in whom blood was drawn within 1 week before surgery. Hyponatremia remained significantly and independently associated with an increased risk of thromboembolism, mortality, composite morbidity, major bleeding, return to operation room and readmission (Table
5). Hypernatremia also remained significantly and independently associated with an increased risk of thromboembolism, mortality, composite morbidity, major bleeding and return to operation room.
Table 5
Sensitivity analysis of outcomes for Na levels taken ≤7 days prior to surgery
Thromboembolism | 1.40 (1.32–1.49) | Reference | 1.66 (1.46–1.89) |
Mortality | 1.36 (1.30–1.41) | Reference | 1.40 (1.28–1.53) |
Composite morbiditya | 2.04 (2.00–2.08) | Reference | 3.86 (3.67–4.06) |
Wound | 1.27 (1.22–1.32) | Reference | 1.28 (1.15–1.43) |
Cardiac | 1.24 (1.17–1.31) | Reference | 1.42 (1.24–1.62) |
Respiratory | 1.67 (1.62–1.72) | Reference | 1.96 (1.82–2.11) |
Urinary | 2.07 (1.96–2.19) | Reference | 4.22 (3.78–4.70) |
CNS | 1.36 (1.24–1.49) | Reference | 2.34 (1.95–2.81) |
Sepsis | 1.65 (1.59–1.70) | Reference | 2.20 (2.04–2.38) |
Bleeding | 1.81 (1.76–1.86) | Reference | 2.10 (1.96–2.26) |
Return to operation room | 1.43 (1.39–1.47) | Reference | 1.47 (1.37–1.58) |
Readmission (related)b | 1.19 (1.12–1.25) | Reference | 0.87 (0.73–1.03) |
Discussion
In this study, we assessed pre-operative hypo- and hypernatremia in patients across all surgical specialties by analyzing data from the ACS NSQIP database. Hyponatremia and hypernatremia were both significantly and independently associated with postoperative thromboembolism, mortality, morbidity, major bleeding and return to operation room. Only hyponatremia was associated with hospital readmission.
The reported incidence of hyponatremia upon hospital admission ranges from 5 to 30% depending on the study population and timing of serum sodium measurements [
20‐
23]. We report a 7.89% rate of pre-operative hyponatremia among surgical patients. Hyponatremia has been associated with increased mortality in patients with pre-existing acute kidney injury [
24], chronic kidney disease [
25], heart failure [
26‐
29], COPD [
30], hip fractures [
31], and intracerebral hemorrhage [
32]; in patients undergoing cardiac transplantation [
33]; and in unselected inpatients with hyponatremia [
9,
34,
35]. The reported mortality rate ranges from 5.2 to 22% [
8,
21,
22,
34,
36]. Our study had a 5.12% mortality rate among hyponatremic patients, similar to that reported by Leung et al. (5.2%), Waikar et al. (5.4%) and Zilberger et al. (5.9%). However, our mortality rate was lower than that reported by Holland-Bill et al. (8.1%) and much lower than that reported by Sturdik et al. (22%). The higher mortality rates reported by Holland-Bill et al. and Sturdik et al. may be related to their study populations, which included patients who were admitted to the internal medicine department. In contrast, our study population and that of Leung et al. involved surgical patients, and studies by Zilberberg et al. and Waiker et al. included a more general patient population. Increased morbidity [
8,
28,
30] and 30-day hospital readmissions [
26,
37] have also been reported in patients with hyponatremia. Hyponatremia is a common finding among patients with pulmonary embolism, occurring at rates ranging from 21 to 26% [
10,
11]. In their meta-analysis, Zhou XY et al. reported that in-hospital mortality was 12.9% in hyponatremic patients with pulmonary embolism and 2.3% in normonatremic patients. The mean 30-day mortality was 15.9% in the hyponatremia group and was 7.4% in the normonatremia group [
38]. However, no study has evaluated the direct association between hyponatremia and the development of pulmonary embolism or deep vein thrombosis.
Similar to hyponatremia, hypernatremia was associated with increased mortality in patients undergoing percutaneous endoscopic gastrostomy [
39], cardiothoracic surgery [
40], or cardiac transplantation; in hip fracture patients [
31]; in patients with chronic kidney disease [
25]; in critically ill patients [
41‐
43]; and in patients with traumatic brain injuries [
33,
44]. The reported mortality rate varies greatly, ranging from as low as 5.2% to as high as 82% [
45‐
54]. This discrepancy is mainly due to data from elderly patients [
46,
47,
49,
50] and on which cutoff value is used to define hypernatremia [
51‐
54]. However, using a study population similar to ours, Leung et al. reported hypernatremia in 2.2% of surgical patients compared with 1% in our population and a mortality rate of 5.2%, which is close to our 9.16% mortality rate [
12]. The authors similarly reported that hypernatremia predicted the occurrence of perioperative major coronary events, pneumonia, and VTE [
12]. Our analysis was extended to evaluate the association of both hyponatremia and hypernatremia with the occurrence of thromboembolic events.
Postoperative thromboembolism within a time frame of 30 days occurred in 2.49% of patients with hypernatremia and 1.8% of patients with hyponatremia. Leung et al. reported thromboembolism among 1.8% of hypernatremic patients [
12]. We found that the effect of hyponatremia on thromboembolic outcome was evident across all age groups, both sexes, patients with or without steroid treatment, patients with a BMI > 18.5, patients with or without cancer and patients with or without chemotherapy. However, hyponatremia was not associated with thromboembolic events in orthopedic patients. The effect of hypernatremia on thromboembolic outcome was also evident across all age groups, both sexes, patients with a BMI > 18.5, and patients with or without cancer. However, hypernatremic patients undergoing orthopedic surgery and patients on chemotherapy and steroids did not develop thromboembolisms. VTE is a serious complication following major orthopedic surgery, and all patients undergoing orthopedic surgery receive thromboprophylaxis with a pharmacological agent or Intermittent Pneumatic Compression Device (IPCD) for a minimum of 10 to 14 days, sometimes extending prophylaxis up to 35 days [
55]. This prophylaxis could explain why hyponatremic and hypernatremic patients undergoing orthopedic surgery were not at risk of developing VTE. Systemic glucocorticoid use increases the risk of VTE among present, new, continuing and recent users but not among former users [
56]. Corticosteroid therapy is associated with a nearly 5-fold increase in the risk of VTE [
57]. Surgical patients with prolonged pre-operative glucocorticoid intake are at a higher risk of developing postoperative VTE and secondary outcomes, including all-cause mortality, urinary tract complications sepsis, wound occurrences, cardiac and respiratory adverse events [
58]. This observation suggests that hyponatremic and hypernatremic patients on steroids are at risk for VTE. However, hypernatremic patients on steroids did not show an increased risk of VTE in our study. Hypernatremia is sometimes encountered in patients with hypertension secondary to aldosteronism [
59]. Medical treatment involves the use spironolactone (aldosterone antagonist or Amiloride) in addition to angiotensin-converting enzyme inhibitors for better control of blood pressure [
60]. Chae et al. recently reported that after controlling for factors related to VTE, the use of renin-angiotensin inhibitors was still associated with a significantly lower risk of developing VTE [
61], which may explain why hypernatremic patients in our study receiving steroids were protected against VTE.
Chemotherapy use in cancer patients increases the risk of VTE 6.5-fold compared with non-cancer patients [
62]. Salahudeen et al. recently reported that 90% of hypernatremia cases among cancer patients are hospital acquired and largely involve leukemia and stem cell transplant patients. The authors also found that, compared with patients with normo- or hyponatremia, patients with hypernatremia were extremely sick and frequently admitted to critical care units [
63]. Our results reveal that hypernatremic patients receiving chemotherapy were not at risk of developing VTE, which may be attributed to this high-risk population receiving thromboprophylaxis treatment. The guidelines on VTE prevention in oncology from the United States National Comprehensive Cancer Network [
64,
65] and the American Society of Clinical Oncology [
66] suggest that thromboprophylaxis should be considered for high-risk ambulatory patients with cancer who receive chemotherapy.
The limitations of this work include a current shortage of biological data on the plausibility of the link between hypernatremia and postoperative thromboembolism. The association between hyponatremia and pulmonary embolism has been established. However, this association has not been established for deep vein thrombosis. Second, in the ACS NSQIP database, only one pre-operative serum sodium value is available and there was large variability in the collection and timing of preoperative blood work. However, sensitivity analyses suggested that risks were similar in patients with sodium measurements taken within 1 week of surgery. Third, patients are followed after surgery for 30 days thus omplications or death after that period are not included. Fourth, around 260,123 (19.0%) individuals out of 1,368,827 were excluded due to missing values on sodium levels. This selection bias has not been accounted for in this study.. Fifth, patients with severe cases of both hyponatremia and hypernatremia likely received some form of treatment. Thus, the incidence of hyponatremia and hypernatremia reported in our study may not be representative of the rates on the day of surgery. Finally, since this study aims at studying causality between sodium imbalances and VTE using a large retrospective dataset, much confounding remains unaddressed despite our careful adjustment for many clinically and statistically relevant factors. For instance, we cannot exclude the possibility of unmeasured confounding factors such as the use of diuretics and DVT prophylaxis, which is unavailable in the ACS NSQIP database analyzed. Thus, it is still not clear whether the associations between both hyponatremia and hypernatremia and increased risk of VTE, morbidity and mortality are due to the adverse effects of sodium imbalances or the underlying diseases. Future work needs to be performed to establish whether sodium imbalance is in fact a causal factor for post-operative VTE.